AMI Asset Management Corp Takes Position in Inari Medical, Inc. (NASDAQ:NARI)

AMI Asset Management Corp bought a new stake in Inari Medical, Inc. (NASDAQ:NARI) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 32,343 shares of the company’s stock, valued at approximately $1,651,000.

Other large investors also recently bought and sold shares of the company. GAMMA Investing LLC grew its stake in shares of Inari Medical by 67.2% in the 3rd quarter. GAMMA Investing LLC now owns 1,177 shares of the company’s stock worth $49,000 after buying an additional 473 shares in the last quarter. KBC Group NV lifted its holdings in shares of Inari Medical by 39.0% in the 3rd quarter. KBC Group NV now owns 1,774 shares of the company’s stock valued at $73,000 after acquiring an additional 498 shares during the last quarter. Benjamin F. Edwards & Company Inc. grew its position in Inari Medical by 39.4% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock worth $89,000 after acquiring an additional 522 shares in the last quarter. Covestor Ltd increased its stake in Inari Medical by 63.5% during the third quarter. Covestor Ltd now owns 2,384 shares of the company’s stock worth $99,000 after acquiring an additional 926 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Inari Medical during the second quarter worth approximately $104,000. Institutional investors own 90.98% of the company’s stock.

Inari Medical Stock Performance

NASDAQ:NARI opened at $79.55 on Tuesday. The company’s 50-day simple moving average is $58.08 and its 200-day simple moving average is $50.90. Inari Medical, Inc. has a fifty-two week low of $36.73 and a fifty-two week high of $79.69.

Insider Buying and Selling at Inari Medical

In other news, Director William Hoffman sold 60,000 shares of the stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $51.16, for a total value of $3,069,600.00. Following the transaction, the director now directly owns 501,233 shares of the company’s stock, valued at approximately $25,643,080.28. This represents a 10.69 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Andrew Hykes sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total value of $150,000.00. Following the completion of the transaction, the chief executive officer now owns 445,310 shares of the company’s stock, valued at approximately $22,265,500. The trade was a 0.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 366,000 shares of company stock worth $20,821,070 over the last three months. Corporate insiders own 10.60% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on NARI shares. Oppenheimer initiated coverage on Inari Medical in a report on Tuesday, December 17th. They issued an “outperform” rating and a $75.00 target price for the company. Canaccord Genuity Group reaffirmed a “hold” rating and set a $80.00 price objective (up from $74.00) on shares of Inari Medical in a research note on Tuesday, January 7th. William Blair reiterated a “market perform” rating on shares of Inari Medical in a research report on Tuesday, January 7th. Robert W. Baird restated a “neutral” rating and issued a $80.00 target price (down previously from $81.00) on shares of Inari Medical in a report on Tuesday, January 7th. Finally, Truist Financial increased their price target on Inari Medical from $50.00 to $63.00 and gave the stock a “hold” rating in a report on Wednesday, December 18th. Twelve equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $68.00.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.